Recently NIH updated their recommendations for treatment of COVID-19. The guidelines dictates that before using MCA’s, one must consider and rule out the use of Paxlovid and/or Remdesivir. It is very likely that the insurance companies will follow this guidelines. This means a valid reason must me present to chose MCA’s over the other two and superiority of this medication is not good enough. Lack of a valid reason will mean that the patient will be responsible for the entire cost. Soon MCA’s will be available commercially and not through the government. Although, this will increase the accessibility to this medication, but at $2100 plus per dose, not a whole lot of folks will be able to afford it. Please take care of yourselves, we are expecting a much higher than normal volume for this flu season.